Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Prevention of stroke or systemic embolism Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND Patient must have non-valvular atrial fibrillation, AND Patient must have one or more risk factors for developing stroke or systemic embolism. Risk factors for developing stroke or systemic ischaemic embolism are: (i) Prior stroke (ischaemic or unknown type), transient ischaemic attack or non-central nervous system (CNS) systemic embolism; (ii) age 75 years or older; (iii) hypertension; (iv) diabetes mellitus; (v) heart failure and/or left ventricular ejection fraction 35% or less.
Prevention of venous thromboembolism Clinical criteria: Treatment criteria: Patient must be undergoing total hip replacement. Patient must require up to 20 days supply to complete a course of treatment.
“Dabigatran is a competitive (Ki = 4.5 nM) and reversible direct thrombin inhibitor and is the main metabolite of dabigatran etexilate in plasma.”
“After Cmax, plasma concentrations of dabigatran showed a biexponential decline with a mean terminal half-life of 12–14 hours in elderly healthy volunteers and 14–17 hours in patients undergoing major orthopaedic surgery.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.